Spero Therapeutics - SPRO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View SPRO analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price targets for Spero Therapeutics' stock. Their SPRO share price forecasts range from $5.00 to $7.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 460.7% from the stock's current price.
View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts.

Spero Therapeutics' stock was trading at $16.01 at the start of the year. Since then, SPRO stock has decreased by 93.3% and is now trading at $1.07.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SPRO earnings forecast.

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.04. The company had revenue of $3.06 million for the quarter, compared to analysts' expectations of $3 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 151.75% and a negative net margin of 1,147.64%. During the same quarter in the prior year, the firm earned ($0.86) earnings per share.

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.86%), Millennium Management LLC (0.96%), AQR Capital Management LLC (0.47%), Assenagon Asset Management S.A. (0.40%), State Street Corp (0.31%) and Northern Trust Corp (0.21%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPRO stock can currently be purchased for approximately $1.07.

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $37.52 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

The company employs 146 workers across the globe.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.